Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

Partner | Cancer Centers | <b>MD Anderson</b>

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms (BPDCL).

BPDCL is an extremely rare hematologic malignancy, and there are currently no FDA-approved therapies to treat this disease. The novel agent SL-401 targets CD123, which is expressed in almost all patients with BPDCL, says Pemmaraju. In a phase II trial, SL-401 demonstrated a manageable and consistent side effect profile with an overall response rate of 90%. The only clinical background on SL-401 before this phase II was a pilot study that showed response in 7 out of 9 patients, which is a large group in this disease, Pemmaraju says.

According to investigators, a biologics license application is being prepared for SL-401 based on the results of this phase II study. The agent is also being investigated in other trials of patients with myelofibrosis, multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome.